Aktuellt
SENASTE
As is usual, costs were well controlled in Q2, and the clinical programme remains on track in the wake of the recent share issue. Equally importantly, Fluoguide strengthened its organisation with a number of key recruitments, adding to the team’s development and deal-making expertise. Our equity valuation range mid-point estimate remains SEK 181 per share.
LÄS MER
